低剂量SM/FP与中等剂量BUD干粉吸入治疗支气管哮喘患者的疗效

摘要

目的：研究支气管哮喘患者应用低剂量沙美特罗/丙酸氟替卡松干粉剂（SM/FP）与中等剂量布地奈德干粉（BUD）吸入治疗的临床效果。方法：回顾分析我院2013年5月～2015年5月收治的95例支气管哮喘患者的临床资料，根据患者的临床治疗方式将其分为研究组与对照组，对照组47例患者单纯应用中等剂量BUD吸入治疗，研究组48例患者在对照组基础上联用低剂量SM/FP吸入治疗。结果：研究组咳嗽症状缓解时间、气短胸闷消失时间、哮鸣音消失时间与对照组对比，P＜0.05。研究组患者治疗后肺功能FEV1、FEV1%、FEV1/FVC、PEF水平均明显优于对照组，P＜0.05，且治疗后血清MMP-9、TIMP-1水平较对照组降低明显，有统计学意义。对照组治疗后血清CD62E、CD62P水平较研究组降低明显，P＜0.05。结论：支气管哮喘患者应用低剂量沙美特罗/丙酸氟替卡松干粉剂、中等剂量布地奈德吸入治疗的临床疗效显著。%Objective: Low dose research on bronchial asthma patients SM/FP with medium doses BUD the clinical effect of inhalation therapy.Methods:Retrospective analysis of our hospital from May 2013 to May 2015 were the clinical data of 95 patients with bronchial asthma,according to the patient's clinical treatment group and control group,control group patients with pure BUD medium dose inhaled treatment,team based part patients in the control group treated with low dose of SM/FP inhaled.Results:Team cough symptoms disappear time disappear,shortness of breath,chest tightness,wheezing sound time and compared with the control groupP<0.05.Group after treatment in patients with lung function FEV1,FEV1,FEV1 / FVC%,PEF levels were significantly better than the control group,P<0.05,and after treatment serum levels of MMP - 9 and TIMP - 1 and serum IL - 17,IL - 33,INF - gamma levels lower significantly than control group,P<0.05.Conclusion:With low doses of bronchial asthma patients nimesulide overlapping,moderate dose of budesonide inhalation therapy,the clinical curative effect is distinct.